Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of ‘on treatment’ type 2 diabetes mellitus (T2DM) versus placebo in patients with prediabetes and obesity. Whether this treatment affects the natural history of the progression from prediabetes to T2DM remains to be established.
Refers to le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399-1409 (2017)